I think UNVC will be in charge of Merck's prescription cannabis drug program, from seed to pill. Merck needs to have a super reliable, super legit supplier for all of its Cannabis requirements. Give it to Doc and they won't have to worry about any b/s. Everything will be done in house, so there will be frwer problems from the supply chain. Doc and crew will extract the oils and chemicals, and mix them according to Merck's specifications. Then the FDA approval processes will begin.

All IMO, but it's not that far of a stretch to see this scenario has great benefit to both companies. Regardless if this comes to fruition or not, we absolutely know UNVC will be working with Merck in some capacity. Just that is huge enough. Then consider the Mylan/Pfizer involvement. Another open door to a giant pharmi company.

Just a side note, the Nasdaq pharmaceutical sector is one of the most volatile segments of the entire stock market. With all the drug trials, approvals, rejections, new discoveries, etc......it's see some big swings.